![]() |
AVEO PharmaceuticalsAVEO is a biopharmaceutical company focused on the discovery and development of drugs that target gene products critical for the maintenance and recurrence of established cancers. AVEO is positioned to revolutionize cancer drug discovery and development by employing powerful, proprietary genetic model systems to discover and develop drugs against essential targets critical to the origin, maintenance and spread of malignant tumors. This novel high-throughput in vivo technology platform enables the rapid functional identification and prioritization of only the most relevant drug targets – dramatically improving the efficiency of drug discovery. Additionally, by identifying patient populations likely to be responsive to drug therapy, AVEO’s technology enables smarter drug development, decreased development costs and improved attrition. Recent NewsAveo Pharmaceuticals Files to Raise $81 Million in IPOAVEO Pharmaceuticals Files Registration Statement for Initial Public OfferingAVEO Pharmaceuticals to Present at IBC’s New Frontiers in Cancer Drug Development ConferenceOSI Pharmaceuticals and AVEO Pharmaceuticals Expand Oncology Discovery and Translational Research CollaborationAVEO Pharmaceuticals Granted Patent for Predictive Biomarker Used to Identify Human Tumors Likely to Respond to Notch Pathway InhibitionAveo Kidney Cancer Drug, Challenging Pfizer and Bayer, Passes Important TestAVEO Initiates Phase 1b/2a Clinical Trial of Novel, Triple VEGF Receptor Inhibitor AV-951 in Non-Small Cell Lung Cancer |
![]() CEOTuan Ha-NgocContact Info75 Sydney Street4th Floor Cambridge, Massachusetts 02139 Phone: 617.299.5000 Fax: 617.995.4995 Key LinksWebsiteJobs Info Highland Team Bob Higgins
|